NCT00380354 is a Phase 2 clinical trial of GSK256066 in Asthma, sponsored by GlaxoSmithKline.

Who is sponsoring NCT00380354?

NCT00380354 is sponsored by GlaxoSmithKline.

What drugs are being tested in NCT00380354?

Interventions in NCT00380354: GSK256066.

What condition does NCT00380354 study?

NCT00380354 studies Asthma, Mild Asthma.

Is NCT00380354 still recruiting?

NCT00380354 is currently completed. Last updated 31 May 2012.

Last reviewed 2012-05-31 · How we verify

NCT00380354

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Two-centre, Randomised, Double-blind, Placebo-controlled, 2-period Cross-over Study to Evaluate the Effect of Treatment With Repeat Doses of Inhaled GSK256066 on the Allergen-induced Late Asthmatic Response in Subjects With Mild Asthma

Completed Phase 2 Last updated 31 May 2012

What this trial tests

Phase 2 trial testing GSK256066 in Asthma in 11 participants. Completed in 1 June 2007.

Timeline

1 September 2006

1 June 2007

Quick facts

Lead sponsor	GlaxoSmithKline
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	treatment
Enrollment	11
Start date	1 September 2006
Estimated completion	1 June 2007
Sites	2 locations across United Kingdom

Drugs / interventions tested

GSK256066 — full drug profile →

Conditions studied

Asthma — all drugs for Asthma →
Mild Asthma — all drugs for Mild Asthma →

Sponsor

GlaxoSmithKline — full company profile →

Who can join

18 and older, any sex, with Asthma or Mild Asthma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Asthmatic response
Time frame: after 7 days of treatment

Sponsor's own description

This study will evaluate the efficacy and safety of GSK256066 in the treatment of subjects with mild bronchial asthma, using a number of clinical and biological markers of efficacy.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma.
Singh D, Petavy F, Macdonald AJ, Lazaar AL, et al · · 2010 · cited 58× · PMID 20193079 · DOI 10.1186/1465-9921-11-26
Recent developments of phosphodiesterase inhibitors: Clinical trials, emerging indications and novel molecules.
Bondarev AD, Attwood MM, Jonsson J, Chubarev VN, et al · · 2022 · cited 52× · PMID 36506513 · DOI 10.3389/fphar.2022.1057083

Verify or expand the search:

Other trials of GSK256066

Trials testing the same drug.

NCT00549744 — Clinical Endpoint Trial Investigating Once Daily and Bronchodilator Dosing · Phase 2 · completed
NCT00549679 — Study To Evaluate Safety And Tolerability Of GSK256066 In Chronic Obstructive Pulmonary Disease (COPD) Patients · Phase 2 · completed
NCT00515268 — Endotoxin Challenge Study For Healthy Men and Women · Phase 1 · completed
NCT00464568 — A 5-way Treatment Period Trial of Single Doses of Intranasal GSK256066 in Patients With Rhinitis · Phase 2 · completed

Other recruiting trials for Asthma

Currently open trials in the same condition.

NCT07525375 — A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared t · Phase 2 · recruiting
NCT07536256 — Community Connections Through Native Hawaiian Cultural Values to Strengthen Youth Resilience, Health, and Well-Being · NA · recruiting
NCT07556159 — A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice · recruiting
NCT07282886 — VENTURI (VENTilation Using Respiratory Imaging) · Phase 2 · recruiting
NCT07433569 — A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Differ · Phase 1 · recruiting

Other GlaxoSmithKline trials

Trials by the same sponsor.

NCT07569081 — A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflam · Phase 2, PHASE3 · not yet recruiting
NCT07406347 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose · Phase 1 · not yet recruiting
NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting
NCT07286331 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-E · Phase 3 · not yet recruiting
NCT07406334 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00380354 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by GlaxoSmithKline
Last refreshed: 31 May 2012

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00380354.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing